Murphy, F., Church, D., Medley, L., Davies, J., Breen, D., Clelland, C., . . . Talbot, D. (2011). PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.
Citazione stile Chigago Style (17a edizione)Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.
Citatione MLA (9a ed.)Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.